Myriad Genetics INC Form 4 insider transactions

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports disposing of shares to cover tax withholding obligations related to vesting restricted stock units.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of shares to cover tax withholding obligations related to vesting restricted stock units.

Kevin Richard Haas, Chief Technology Officer of Myriad Genetics, reported the disposal of common stock to cover tax withholding obligations related to vesting restricted stock units.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Chief Commercial Officer Mark Verratti of Myriad Genetics reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Paul J. Diaz, President and CEO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units.

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports acquisition and disposal of common stock and restricted stock units.

Shereen Solaiman, Chief People Officer of Myriad Genetics, reports acquisition of restricted stock units and disposition of shares to cover tax obligations.

Chief Technology Officer Kevin Richard Haas of Myriad Genetics Inc. reports acquisition and disposal of common stock due to vesting of restricted stock units and tax withholding.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units.

Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics, reports the acquisition of 63,145 shares of common stock and the disposal of 124,916 shares.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units and tax obligations.

Scott Leffler, CFO of Myriad Genetics, reports acquisition of restricted stock units and disposition of shares to cover tax obligations.

Chief Operating Officer of Myriad Genetics, Samraat S. Raha, reports acquisition and disposal of company stock, including restricted stock units and shares withheld for tax obligations.

Paul Diaz, CEO of Myriad Genetics, disposed of shares to cover tax obligations related to vesting restricted stock units.

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the acquisition of 3,316 shares of common stock on February 7, 2025, related to performance-based restricted stock units.

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the acquisition of 6,468 shares of common stock on February 7, 2025, related to performance-based restricted stock units.

Chief Technology Officer Kevin Richard Haas reports acquisition and disposal of Myriad Genetics stock and performance-based restricted stock units.

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, acquired 10,622 shares of common stock on February 7, 2025, through the vesting of performance-based restricted stock units.

Mark Verratti, Chief Commercial Officer of Myriad Genetics, acquired 12,758 shares of common stock on February 7, 2025, following the vesting of performance-based restricted stock units (PSUs).

Paul J. Diaz, President and CEO of Myriad Genetics, acquired 114,828 shares of common stock on February 7, 2025, following the vesting of performance-based restricted stock units (PSUs).

Shereen Solaiman, Chief People Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the disposal of 2,697 shares to cover tax obligations related to vesting restricted stock units.

Chief Technology Officer Kevin Richard Haas of Myriad Genetics Inc. reports the withholding of 1,016 common stock shares to cover tax obligations related to vesting restricted stock units on February 25, 2025.

Scott Leffler, CFO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Myriad Genetics' Chief Scientific Officer, Dale Muzzey, sold 417 shares of common stock on January 1, 2025, to cover tax obligations related to vesting restricted stock units.

Myriad Genetics' Chief Operating Officer, Samraat S. Raha, sold shares to cover tax obligations related to vested restricted stock units.

Myriad Genetics Inc. executive Mark Steven Davis was granted 22,816 restricted stock units under the company's 2017 equity incentive plan.

Myriad Genetics Chief Operating Officer, Samraat S. Raha, acquired 1,118 shares of common stock through the company's employee stock purchase plan.